Neuromuscular diseases

News

Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.

News

Novartis has suffered another pipeline blow, this time involving its highly anticipated neuromuscular disease therapy del-desiran.

News

FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.

News

Several years after other UK nations, people living with multiple sclerosis in England are finally able to get NHS treatment with fampridine.

News

Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.

News

Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.